Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: BAT2206

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: $150.0 million Upfront Cash: $20.0 million

            Deal Type: Licensing Agreement August 27, 2021

            Details:

            Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206. Hikma will have exclusive rights to commercialize the product in the US.